Anticoagulation in Real-Life Patients with Atrial Fibrillation: Impact of Renal Disease

Undas, Anetta

Journal Metrics

Impact Factor (2022): 1.3
5-Year Impact Factor: 1.5
Eigenfactor Score: 0.00148
CiteScore (2022): 1.9
SCImago Journal Rank: 0.29

28/5Current Issue Ahead of Print Archive Most Accessed Articles

Quick Search

In authors and institutes

In titles and abstracts

In keywords

In all

The Anatolian Journal of Cardiology

Anticoagulation in Real-Life Patients with Atrial Fibrillation: Impact of Renal Disease [Anatol J Cardiol]

Anatol J Cardiol. 2023; 27(1): 54-55 | DOI: 10.14744/AnatolJCardiol.2022.2333

Anticoagulation in Real-Life Patients with Atrial Fibrillation: Impact of Renal Disease

Anetta Undas
Department of Thromboembolic Diseases, Institute of Cardiology, Jagiellonian University Medical College, Kraków, Poland; Center for Research and Innovative Technology John Paul II Hospital, Kraków, Poland

Anetta Undas. Anticoagulation in Real-Life Patients with Atrial Fibrillation: Impact of Renal Disease. Anatol J Cardiol. 2023; 27(1): 54-55

Corresponding Author: Anetta Undas
Manuscript Language: English

TOOLS Full Text PDF Print Download citation RIS EndNote BibTex Medlars Procite Reference Manager Share with email Share Similar articles PubMed Google Scholar